Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy.
A 58-year-old man with known metastatic clear cell RCC was imaged with both F-FDG and F-DCFPyL PET/CT. F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to F-FDG, F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.
Clinical nuclear medicine. 2015 Sep 22 [Epub ahead of print]
Steven P Rowe, Michael A Gorin, Hans J Hammers, Martin G Pomper, Mohammad E Allaf, Mehrbod Som Javadi
From the *The Russell H. Morgan Department of Radiology and Radiological Science; †The James Buchanan Brady Urological Institute and Department of Urology; and ‡Department of Medical Oncology at the Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD.